Drug Combination Details
| General Information of the Combination (ID: C02157) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | Trichostatin A Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lymphoma
[ICD-11: 2A80-2A86]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDKN2A | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | CA46 | CVCL_1101 | Burkitt lymphoma | Homo sapiens | ||
| Experimental
Result(s) |
Epigallocatechin-3-gallate and trichostatin A synergistically inhibit human lymphoma cell proliferation through epigenetic modification of p16INK4a. | |||||
